A role for loss of p53 function in sensitivity of ovarian carcinoma cells to taxanes
- 30 April 2001
- journal article
- research article
- Published by Wiley in International Journal of Cancer
- Vol. 92 (5) , 738-747
- https://doi.org/10.1002/1097-0215(20010601)92:5<738::aid-ijc1249>3.0.co;2-2
Abstract
No abstract availableKeywords
This publication has 23 references indexed in Scilit:
- p53 Gene Status and Response to Platinum/Paclitaxel-Based Chemotherapy in Advanced Ovarian CarcinomaJournal of Clinical Oncology, 2000
- Molecular mechanisms of resistance to taxanes and therapeutic implicationsDrug Resistance Updates, 1999
- Molecular effects of paclitaxel: Myths and reality (a critical review)International Journal of Cancer, 1999
- A novel charged trinuclear platinum complex effective against cisplatin-resistant tumours: hypersensitivity of p53-mutant human tumour xenograftsBritish Journal of Cancer, 1999
- Inactivation of p53 in a Human Ovarian Cancer Cell Line Increases the Sensitivity to Paclitaxel by Inducing G2/M Arrest and ApoptosisExperimental Cell Research, 1998
- Ovarian cancer cisplatin-resistant cell lines: Multiple changes including collateral sensitivity to TaxolAnnals of Oncology, 1998
- Anti-proliferative activity of a new class of taxanes (14β-hydroxy-10-deacetylbaccatin III derivatives) on multidrug-resistance-positive human cancer cellsInternational Journal of Cancer, 1997
- p53-independent apoptosis induced by paclitaxel through an indirect mechanismProceedings of the National Academy of Sciences, 1997
- p53 in drug resistance in ovarian cancerThe Lancet, 1997
- 14β-Hydroxy-10-deacetylbaccatin III, a new taxane from Himalayan yew (Taxus wallichiana Zucc.)Journal of the Chemical Society, Perkin Transactions 1, 1992